'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Biocon has increased 14.83% to Rs 3941.9 crore. Sales of Generics segment has gone up 5.64% to Rs 696.50 crore (accounting for 17.29% of total sales). Sales of Biosimilars segment has gone up 17.97% to Rs 2,457.80 crore (accounting for 61.01% of total sales). Sales of Research service segment has gone up 10.74% to Rs 874.50 crore (accounting for 21.71% of total sales). Inter-segment sales came down from Rs 99.50 crore to Rs 86.90 crore.
Profit before interest, tax and other unallocable items (PBIT) has slumped 88.68% to Rs 130.30 crore. PBIT of Generics reported loss of Rs 67.00 crore compared to profit of Rs 16.90 crore. PBIT of Biosimilars segment fell 90.98% to Rs 96.00 crore (accounting for 73.68% of total PBIT). PBIT of Research ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|